SunRISe-1 Data: Promising Complete Response Rate, Durable Outcomes With TAR-200 for NMIBC

Описание к видео SunRISe-1 Data: Promising Complete Response Rate, Durable Outcomes With TAR-200 for NMIBC

Sia Daneshmand, MD, discusses the groundbreaking findings from the SunRISe-1 study, highlighting TAR-200’s impressive complete response rates as a monotherapy for BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. Dr. Daneshmand describes how TAR-200’s sustained drug delivery sets it apart from conventional intravesical therapies, offering a promising new approach to bladder-sparing strategies. He delves into the study’s safety, tolerability, and durable responses, as well as its potential to supplement or delay the need for radical cystectomy in eligible patients.

Комментарии

Информация по комментариям в разработке

Похожие видео